Blagden, Sarah <br/><br/>
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Dec 2014 
 - 5908-17 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-14-1315  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Antineoplastic Agents--pharmacology<br/>Class I Phosphatidylinositol 3-Kinases--antagonists & inhibitors<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Neoplasms--diagnosis<br/>Positron-Emission Tomography<br/>Pyrimidines--pharmacology<br/>Sulfonamides--pharmacology<br/>Tomography, X-Ray Computed<br/>Treatment Outcome